Large gap with delayed quotes
|
Official
03/16/2026
-
17:35:07
|
Bid
03/16/2026 -
18:30:00
|
Bid Volume |
Ask
03/16/2026 -
18:30:00
|
Ask Volume |
|---|---|---|---|---|
|
12.6600
+0.26
(
+2.10% )
|
11.9500
|
1,000 |
15.1900
|
380 |
Analysis date: 13.03.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 03.03.2026.
Interest
Strong
Strong
Three stars since 03.03.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 03.03.2026 at a price of 1247.00.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Negative
Negative
The stock appears oversold from a technical perspective due to its recent losses. It trades below its forty day technical trend since 27.02.2026.
4wk Rel Perf
-17.83%
-17.83%
The stock appears oversold from a technical perspective, with a four week dividend-adjusted underperformance of of 17.83% behind the STOXX600.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 27.02.2026.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.04%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.75%.
Mkt Cap in $bn
3.60
3.60
With a market capitalization between $2 & $8bn, HIKMA PHARMACEUTICALS is considered a mid-cap stock.
G/PE Ratio
1.63
1.63
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
6.90
6.90
The estimated PE is for the year 2028.
LT Growth
6.02%
6.02%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
8
8
Over the last seven weeks, an average of 8 analysts provided earnings per share estimates.
Dividend Yield
5.20%
5.20%
The twelve month estimated dividend yield represents 35.85% of earnings forecasts.
Beta
61
61
For 1% of index variation, the stock varies on average by 0.61%.
Correlation
0.28
0.28
Stock movements are strongly independent of index variations.
Value at Risk
148.92
148.92
The value at risk is estimated at GBp 148.92. The risk is therefore 12.01%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
11.10.2006
11.10.2006